CARIPRAZINE capsules (Reagila®▼) for Schizophrenia in Adults

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of Cariprazine capsules (Reagila®▼), for the treatment of schizophrenia in adult patients.

GREY

This recommendation will be reviewed within 6 months of the product launch in the UK market, following a full assessment of the evidence by the New Medicines Sub Group.

Cariprazine (Reagila®▼) is a new second generation antipsychotic with partial agonist activity at dopamine D_2, D_3, and serotonin $5\text{-}HT_{1A}$ receptors, as well as antagonist activity at serotonin $5\text{-}HT_{2B}$, $5\text{-}HT_{2A}$ and histamine H_1 receptors. It is indicated for the treatment of schizophrenia in adult patients[1].

A range of alternative first and second generation antipsychotics are available. Recommendations for the treatment of schizophrenia are available from NICE clinical guideline CG178: Psychosis and schizophrenia in adults: prevention and management[2], published February 2014; last updated March 2014.

References

1. Recordati Pharmaceuticals Limited. Summary of Product Characteristics: Reagila hard capsules. Accessed 20 September 2018 at: https://www.medicines.org.uk/emc/search?q=cariprazine

2. NICE clinical guideline CG178: Psychosis and schizophrenia in adults: prevention and management. Published February 2014; Last updated March 2014. Accessed 20 September 2018 at: https://www.nice.org.uk/guidance/cg178

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

APC board date: 26 SEP 2018
Review date: September 2020
or earlier if there is significant new evidence relating to this recommendation

Prescribing policy statement
Version: 1.0